Last reviewed · How we verify

Oral Melatonin (4 mg) — Competitive Intelligence Brief

Oral Melatonin (4 mg) (Oral Melatonin (4 mg)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Melatonin receptor agonist. Area: Neurology / Sleep Medicine.

phase 3 Melatonin receptor agonist MT1 and MT2 melatonin receptors Neurology / Sleep Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Oral Melatonin (4 mg) (Oral Melatonin (4 mg)) — Woolcock Institute of Medical Research. Melatonin binds to melatonin receptors (MT1 and MT2) to regulate circadian rhythm and promote sleep.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Oral Melatonin (4 mg) TARGET Oral Melatonin (4 mg) Woolcock Institute of Medical Research phase 3 Melatonin receptor agonist MT1 and MT2 melatonin receptors
Oral Bedtime Melatonin Oral Bedtime Melatonin Hospital San Carlos, Madrid marketed Melatonin receptor agonist MT1 and MT2 melatonin receptors
Melatonin PR Melatonin PR Seoul National University Hospital marketed Melatonin receptor agonist MT1 and MT2 melatonin receptors
melatonin in children premedication melatonin in children premedication Azienda Ospedaliera Universitaria Policlinico "G. Martino" marketed Melatonin receptor agonist MT1 and MT2 melatonin receptors
transdermal therapeutic system- melatonin. transdermal therapeutic system- melatonin. Ain Shams University marketed Melatonin receptor agonist MT1 and MT2 melatonin receptors
Sublingual Melatonin Sublingual Melatonin Al-Azhar University marketed Melatonin receptor agonist MT1 and MT2 melatonin receptors
Melatonin Patches Melatonin Patches Ain Shams University marketed Melatonin receptor agonist MT1 and MT2 melatonin receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Melatonin receptor agonist class)

  1. Ain Shams University · 2 drugs in this class
  2. Al-Azhar University · 1 drug in this class
  3. Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 drug in this class
  4. B.P. Koirala Institute of Health Sciences · 1 drug in this class
  5. Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health · 1 drug in this class
  6. Hospital San Carlos, Madrid · 1 drug in this class
  7. Imperial College London · 1 drug in this class
  8. KIMJisun · 1 drug in this class
  9. Rush University Medical Center · 1 drug in this class
  10. Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral Melatonin (4 mg) — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-melatonin-4-mg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: